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The 11th Handbook of Cancer Prevention from the WHO’s International Agency for Research on Cancer presents a comprehensive review of 
the scientific literature and a thorough evaluation, by 
an international group of experts, of the evidence for 
changes in the risk of certain cancers, vascular diseases, 
and lung diseases following smoking cessation. The 
main goal of the handbook is provide scientific evidence 
on the health benefits of smoking cessation in support 
of recommended public health and public policy decis
sions. 
The handbook is organized around the following 
three questions, identifying the research and presenting 
recommendations relevant to each question:
1.  Is the risk of disease lower in former smokers than 
in otherwise similar current smokers?
2.  What is the time course of the reduction in risk 
with continued abstinence or, among otherwise 
similar former smokers, does the risk of disease 
lower with more prolonged abstinence?
3.  Does the risk return to that of never smokers after 
long periods of abstinence?
The answers are presented clearly and succinctly in a 
final section of the 348spage report, which also summas
rizes the level of evidence available for specific diseases 
(Table, next page). The main body of the report deals 
separately, citing full references, with the eventual effects 
of smoking, and of smoking cessation, on cancers of the 
lung, mouth, pharynx, larynx, esophagus, stomach, liver, 
pancreas, kidney, bladder or cervix, as well as heart diss
ease, stroke, other vascular diseases and chronic obstrucs
tive lung disease.  Cancer, chronic obstructive pulmonary 
disease and vascular diseases represent the three main 
causes of smokingsattributable deaths worldwide. While 
individual studies of smoking cessation usually deal with 
one disease, the authors point out that the benefits of 
cessation extend across all of the diseases caused by cigas
rette smoking. “Thus, the examination of changes in spes
cific risks contained in this volume are accurate descrips
tions of the changes in risk for that individual disease, 
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but they dramatically underestimate the total benefit of 
cessation, the sum of the risk reductions for each of the 
specific diseases caused by tobacco smoking.”
 The report is dedicated to Richard Doll (1912s
2005), one of the principal epidemiologists who showed 
that smoking was linked to lung cancer and increased 
the risk of heart disease.  The 50syear results of his study 
showed that smokers lose about 10 years of life expecs
tancy and that stopping smoking regains much or all of 
that life expectancy. Doll smoked for 20 years, quitting 
after the first results of his studies emerged, and lived 
into his ninth decade. In 2005, Dr. Doll received the 
King Faisal International Prize for Medicine, awarded 
by the King Faisal Foundation.
The handbook is US$45 and can be ordered from 
www.who.int/bookorders.
book review BOOK reVieW
Hematol Oncol Stem Cell Ther 1(1)     January 2008 hemoncstem.edmgr.com72
Adequacy	of	evidence	to	address	questions	on	the	effects	of	smoking	cessation	on	risk	of	disease.
Disease Risk	for	Former	Smokers	(1)
Risk	with	Prolonged	
Abstinence	(2)
Residual	Increased	
Risk	(3)
Cancers
lung cancer ¢ ¢ ¢
laryngeal cancer ¢ ¢ ¢
Oral cancer ¢ ¢ ¢
Squamous cell esophageal cancer ¢ ¢ ¢
esophageal adenocarcinoma £ £ £
Stomach cancer ¢ T £
liver cancer T £ £
pancreatic cancer ¢ ¢ T
Bladder cancer ¢ ¢ ¢
renal cancer ¢ T £
Cervical cancer ¢ ¢ ¢
myeloid leukemia +/- £ £
nasopharyngeal cancer T £ £
Sinonasal cancer £ £ £
Vascular Disease
CHD incidence and death in subjects without 
established diseases ¢ ¢ ¢
CHD incidence and death in those with clinical 
evident disease ¢ ¢ not applicable
Cerebrovascular disease incidence and death for 
those without established disease ¢ ¢ T
Cerebrovascular disease incidence and death for 
those with clinical disease £ £ not applicable
aortic aneurysm incidence and death for those with 
established disease ¢ T T
aortic aneurysm incidence and death for those with 
clinical disease ¢ £ not applicable
paD incidence and death for those without 
established disease ¢ T T
paD incidence and death for those with clinical 
disease T T not applicable
lung Disease
Cough and phlegm production ¢ ¢ ¢
Decline in FeV1 in healthy subjects ¢ ¢ ¢
Decline in FeV1 for those with mild/moderate 
disease ¢ ¢ not applicable
Decline in FeV1 for those with severe disease/
morbidity ¢ ¢ not applicable
mortality from COpD ¢ ¢ T
level of evidence to address questions: ¢adequate: The evidence is adequate to draw a clear conclusion on the question; Tlimited: The evidence to answer the question is 
suggestive; the interpretation is considered by the Working Group to be credible, but chance, bias, confounding or other factors cannot be adequately evaluated;
+/b Conflicting: The data provide conflicting answers to the question; £absence of Observations: There is an absence of data or data are inadequate to address the question.
FeV1: Forces expiratory volume in one second; CHD: Coronary Heart Disease; paD: peripheral artery Disease. reproduced with permission, international agency for research on 
Cancer, World Health Organization.
